Trials / Terminated
TerminatedNCT04242173
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is approved for sale in United States by the U.S. Food and Drug Administration (FDA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemiplimab-Rwlc | Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days) |
Timeline
- Start date
- 2020-06-25
- Primary completion
- 2022-05-26
- Completion
- 2022-05-26
- First posted
- 2020-01-27
- Last updated
- 2022-11-04
- Results posted
- 2022-07-14
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04242173. Inclusion in this directory is not an endorsement.